Oncology

A landmark study reveals GLP-1 drugs like Ozempic dramatically reduce risks of depression and anxiety, hinting at a new era for mental healthcare.

After his own diagnosis, golfer Brian Gay advocates for GentleCure, a non-surgical option with a 99% cure rate that kept him on the course.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.

Pharma giant AbbVie taps biotech innovator Alloy Therapeutics to build a novel antibody platform, aiming to unlock a new generation of medicines.

With promising clinical data for its lead drug silevertinib and a strong new financial position, Black Diamond Therapeutics charts a dual course for two deadly cancers.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

As it advances its brain cancer therapies, NeOnc Technologies hires a public company finance expert to steer its next growth phase and ensure fiscal rigor.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

A groundbreaking clinical trial shows a nutrition-based therapy extended life by 34% in stage IV pancreatic cancer patients, offering rare hope.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

As AI progress stalls on bad data, a new research lab is bringing scientific discipline to the industry's most overlooked and critical pillar.

A new clinic led by one of under 500 board-certified vet oncologists offers Seattle a personalized alternative to corporate pet healthcare.

Advocates call for colorectal cancer screening to start at 45 as cases surge in people under 50, raising questions about Canada's readiness.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.